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Received March 30, 2010; accepted November 4, 2010AbstractBackground: Radical retropubic prostatectomy remains the gold standard treatment for localized prostate cancer. However, new minimally
invasive techniques have emerged, providing a less invasive approach. Robotic-assisted laparoscopic radical prostatectomy is the ideal tech-
nique, providing good oncologic and functional outcomes. We analyzed the impact of robotic surgical systems on practice patterns among
urologists to explain changes in the value of radical retropubic prostatectomy, laparoscopic radical prostatectomy and robotic-assisted lapa-
roscopic radical prostatectomy in a single institution in Taiwan.
Methods: We retrospectively reviewed the records of patients who received prostatectomy by one of the above procedures between January 2004
and November 2009. Decisions to perform these procedures were made by patient preference. Patients who received prostate biopsies at other
hospitals were transferred to our hospital specifically for robotic-assisted prostatectomy.
Results: A total of 434 radical prostatectomies were performed, of which 141 (32.49%) were radical retropubic prostatectomies, 59 (13.59%)
were laparoscopic radical prostatectomies and 234 (53.92%) were robotic-assisted laparoscopic prostatectomies. The overall number of pros-
tatectomies has increased over time because of an increase in robotic-assisted procedures. No decreases were seen in the number of radical
retropubic prostatectomies during the evaluation period. Changes in the ratio of robotic-assisted prostatectomies compared to radical retropubic
and laparoscopic radical prostatectomies demonstrated a trend toward robotic-assisted procedures. The percentage of cases transferred from
other hospitals also increased over time from 28.57% to 68.60%.
Conclusion: Our experience emphasizes the potential of robotic-assisted prostatectomy to become the mainstream treatment for localized
prostate cancer in Taiwan.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Prostate cancer is the most common malignant neoplasm
and second leading cause of cancer deaths in the United
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Incidence increased from 8.58/100,000 per year in 1996 to
23.39/100,000 per year in 2005,1 and it became the fifth most
commonly diagnosed cancer. Prostate cancer is currently the
seventh highest cause of cancer deaths (8.6/100,000 per year,
2007) in male patients in Taiwan.2
Widespread screening with serum prostate-specific antigen
(PSA) and digital rectal examination (DRE) has allowed
detection of localized prostate cancer. Options for surgical
treatment of localized prostate cancer now include radical
retropubic prostatectomy (RRP), laparoscopic radicalhinese Medical Association. All rights reserved.
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prostatectomy (RALP). These three surgeries each have
different advantages and disadvantages.3,4 RRP remains the
gold standard procedure because it has demonstrated good
long-term oncologic outcomes and acceptable functional
outcomes. LRP offers reduction of blood loss (secondary to
pneumoperitoneum with increasing abdominal pressure and
better visualization), faster recovery, and better cosmetic
outcomes. However, LRP is a technically challenging opera-
tion with a steep learning curve and poor ergonomics for
surgeons.
The introduction of the da Vinci Surgical System (Intuitive
Surgical Inc., Sunnyvale, CA, USA) in urology in 1999 caused
a revolution in surgical approaches for localized prostate cancer.
RALP preserves the benefits of minimally invasive surgery and
overcomes the drawbacks of LRP. The robotic system provides
several advantages, including three-dimensional stereoscopic
viewing, tenfold optical magnification, computerized elimina-
tion of tremor and intuitive finger-controlledmovement with the
use of an endo-wrist instrument with seven degrees of freedom
of movement. In addition, the ergonomic design of the robotic
control console appears to reduce the muscle strain and fatigue
of surgeons. The learning curve for RALP is faster than that for
LRP. Ahlering et al. reported that the learning curve of a non-
laparoscopic surgeon performing RALP is just 12 cases.5 In our
previous report, the console time was significantly decreased
from 262minutes to 190minutes after 30 cases’ experience, and
the preliminary functional outcomes were also well accepted.6
In Taiwan, the first RALP was performed at Tri-Service
General Hospital, Taipei in 2004. At that time, more and more
patients were receiving RALP. Currently, five hospitals in
Taiwan have a da Vinci Surgical System, and a total of 507
RALP surgeries were performed between 2004 and 2009
(Table 1) (data provided by the Double Success Limited
Company). The annual case numbers increased from 3 to 192
in a 6-year period. A total of 234 cases (45.1%) were per-
formed at Taichung Veterans General Hospital (TCVGH) in
the same time period.
This study examined the impact of robotics on radical
prostatectomy at a single institution (TCVGH) in central
Taiwan over a 6-year period (2004 to 2009). We emphasize
that the surgical treatment trend for localized prostate cancer
will shift to RALP.Table 1
Current da Vinci robotic-assisted laparoscopic radical prostatectomies in
Taiwan
2004 2005 2006 2007 2008 2009
TSGH 3 9 16 23 34 41
CGMH 13 29 31 61
CHGH 2 6 1
TPVHG 4
TCVGH 7 28 50 63 86
Total (N ¼ 507) 3 18 63 102 129 192
CGMH ¼ Chang Gung Medical Hospital; CHGH ¼ Cheng Hsin General
Hospital; TCVGH ¼ Taichung Veterans General Hospital; TPVGH ¼ Taipei
Veterans General Hospital; TSGH ¼ Tri-service General Hospital.2. Methods
This study was a retrospective review of the surgical data-
base of TCVGH. We reviewed and analyzed the records of
patients who received RRP, LPR or RALP between January
2004 and November 2009. All patients had pathologically
confirmed prostate cancer, and surgeries were performed either
by transrectal ultrasonic biopsy or transurethral resection of the
prostate. Also, prostate magnetic resonance imaging and
whole-body bone scans were performed to exclude nodal and
distant metastasis. Decisions to perform RRP, LRP or RALP
were made according to patient preference after each patient
had discussed the risks and benefits of each approach with the
attending surgeon. TCVGH is the only hospital in central
Taiwan that has a da Vinci Surgical System. Patients who had
received prostate biopsies at other hospitals and were trans-
ferred to TCVGH for surgery were identified and included in
our study. Most of them had requested RALP as the surgical
approach. We carried out a survey of the source of RALP in
patients who were referred from other hospitals in the year
2009. We also conducted a survey about motivations for
undergoing robotic surgery including/examining eight issues
(1) postoperative continence rate; (2) cancer control; (3)
erection function preservation; (4) minimal invasion and less
pain; (5) less blood loss without transfusion; (6) short hospital
stay; (7) less care burben for family; (8) private health insur-
ance coverage among 74 patients. Patients were asked to
answer each issue with a score from 1 to 8, from the issue of
greatest/most concerning issue with score 8 to the least con-
cerning issue with score 1.
3. Results
From January 2004 to November 2009, 434 radical prosta-
tectomies were performed at TCVGH. Of the 434 cases, 141
(32.49%) were RRPs, 59 (13.59%) were LRPs and 234
(53.92%) were RALPs. The first RALP was performed in
December 2005, and after that, the percentage of RALPs
gradually increased from 14% to 70.79% in 2008 and remained
at 69.69% in 2009 (Fig. 1). The changes in ratio of RALP to
RRP and LRP demonstrated a trend toward RALP. In addition,
the total number of radical prostatectomy cases also increased
after the emergence of the da Vinci Surgical System. In 2005,
we performed 40 radical prostatectomies, however, in 2009, the
total number rose to 123. Of the 234 RALPs, we found that the
percentage of transferred cases also increased from 28.57% in
2006 to 68.60% in 2009 during the same time period (Fig. 2). In
2009, 59 patients who received RALP were transferred from
other hospital due to doctor’s reference (71.2%), website or
news (15.2%) and family/friends’ recommendation (13.6%).
The five major concerns of patient motivation were cancer
control (score 6.59  1.71), postoperative continence rate
(6.35 1.48), minimal invasion and less pain (5.97 1.30), less
blood loss without transfusion (5.16  1.54) and erection
function preservation (4.22  1.77). Economic consideration
for the private health insurance coverage was the issue of least
concern with score 1.24  0.93.
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Fig. 1. Number of RRP, LRP and RALP procedures performed at TCVGH
from 2004 to 2009. LRP ¼ laparoscopic radical prostatectomy;
RALP ¼ robotic-assisted laparoscopic radical prostatectomy; RRP ¼ radical
retropubic prostatectomy; TCVGH ¼ Taichung Veterans General Hospital.
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Many studies have documented a trend toward RALP being
the choice of treatment for localized prostate cancer. In the
United States, currently, more than 550 da Vinci Surgical
Systems are in operation. In 2006, RALPs constituted only
10% of the total number of radical prostatectomies performed
by American urologists, however, the proportion had increased
to more than 65% in 2008 through 2009.7 The same
phenomenon was also noted in Korea, where RALPs gradually
increased from 8% to 77% (from 2005 to 2008). This gradual
country-to-country increase is called the “halo effect”.8 We
found the same phenomenon to be true at TCVGH; cases have
increased from year to year since the introduction of RALP. Of
the 243 patients in this study, 141 (58.02%) were diagnosed at
other hospitals and transferred to our hospital specifically for
RALP. This conforms to the “halo effect” described above.0 
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Fig. 2. Patients with prostate cancer receivingRALPwere diagnosed at TCVGH
and other hospitals from 2005 to 2009. RALP ¼ robotic-assisted laparoscopic
radical prostatectomy; TCVGH ¼ Taichung Veterans General Hospital.Not only do patients receive RALP as their treatment of
choice, but also there are more urologic surgeons shifting from
RRP to RALP. In 2006, only 3% of surgical residents believed
that laparoscopic robotic prostatectomy was the surgical gold
standard for treating localized prostate cancer.9 Recently, in
a multi-national, questionnaire-based study, 40% of partici-
pants considered RALP to be the gold standard.10 Although
only 21% of respondents were currently performing RALP,
78% of respondents felt it was required or beneficial to have
training in robotic-assisted surgery, and 61% believed they
would perform robotic-assisted surgery.10
Coelho et al.11 reviewed current outcomes of RALP,
including 16 larger and more serious cases among more than
9,000 cases. They emphasized perioperative data, surgical
complications, positive margin rate continence and sexual
potency; the last three are the so-called “trifecta” outcomes.
Generally, comparative studies have shown that RALP is asso-
ciated with less blood loss, a lower transfusion rate and shorter
hospital stays when compared to open radical prostatectomy.
With regard to oncologic outcomes, the overall positive
surgical margin (PSM) rate was 15.2% after RALP, ranging
from 9.3% to 33%.11 Ficarra et al.12 reported that the PSM rate
ranged from 11% to 37% after RRP and from 11% to 30% after
LRP. No significant differences were found between these three
groups. The PSM rate is influenced by the PSA level, Gleason
score and tumor stage. In Patel and coworkers’ review, the PSM
rate range was 0e20% for patients at T2 and 0e75% for T3.13
Excellent functional outcomes were reported in several
large series. RALP with modified technique may enhance
early continence. Nguyen et al.14 reported that posterior
reconstruction of Denonvilliers’ musculofascial plate may
enhance early continence after RALP and LRP. Significantly
higher early continence rates were seen compared to the
control group at 3 days (34% vs. 3%) and at 6 weeks (56% vs.
17%). The authors also described that reconstruction restored
the length of the transected membranous urethra by a mean of
2 mm. Tewari et al.15 described a novel technique for total
reconstruction of the vesico-urethral junction (including
anterior and posterior reconstruction). This group had conti-
nence rates of 38%, 83%, 91%, and 97% at 1, 6, 12, and 24
weeks, respectively. In the group that received either no or
partial reconstruction, the continence rates were significantly
lower less ( p < 0.01). Early postoperative sexual potency
seems to be better with RALP than with RRP and LRP. Kaul
et al.16 reported that 69% of patients had normal erections
after RALP with bilateral nerve sparing. Potdevin et al.17
performed nerve sparing surgery with athermal intrafascial
robotic (AIR) approach, which improved the potency rate from
66.7% to 90.9% within 9 months. Another issue that arises in
comparing the different surgical treatments for localized
prostate cancer is the cost. According to American surgeons
who use the robot, robotic technology might add $1,000 to the
surgical cost of radical prostatectomy, and a total cost of for
RRP is about $24,000.18 In Taiwan, we have national health
insurance and prostate cancer is categorized as a major illness,
which has the benefit of copayment exemptions. LRP needs
additional payment of about NT$50,000 (w$1,550) and
158 C.-L. Liu et al. / Journal of the Chinese Medical Association 74 (2011) 155e158RALP needs about NT$200,000 (w$6,200). This is because of
higher RALP costs relative to the purchase and maintenance of
operative equipment. Nevertheless, RALP is continuing to
grow in popularity because of patient interest, benefits and
demand. In our patients received RALP, economic consider-
ation of private health insurance coverage is the least con-
cerning/important issue. The two main reasons for choosing
RALP were cancer control and postoperative continence rate.
Currently, many new minimally invasive technologies are
available for treating localized prostate cancer. Four modalities
appear to have the greatest clinical promise, including cryo-
therapy, radiation therapy, high-intensity focused ultrasound,
and photodynamic therapy.19 These ablative technologies
can deliver a minimally invasive, one-day surgical treatment
with effective early cancer control and low genitourinary
morbidity.20 These minimally invasive surgeries offer more
options for patients who are not candidates for radical surgery.
In conclusion, RRP is the gold standard for surgical treat-
ment of localized prostate cancer. LRP and RALP provide
minimally invasive surgery, while RALP has conquered the
disadvantages of LRP, including the steep learning curve,
longer operative time and ergonomic discomfort for surgeons.
The impact of robotics is obvious in our institution. The annual
case number of radical prostatectomies is increasing and RALP
surgeries occupy the major portion of that increase. Our expe-
rience emphasizes the potential of RALP to become the main-
stream treatment for localized prostate cancer in Taiwan.
References
1. Department of Health, Executive Yuan, Republic of China. Health and
Vital Statistics; 2005.
2. Department of Health, the Executive Yuan, Republic of China. Health and
Vital Statistics; 2007.
3. Bhayani SB, Pavlovich CP, Hsu TS, Sullivan W, Su LM. Prospective
comparisonof short-termconvalescence: laparoscopic radical prostatectomy
versus open radical retropubic prostatectomy. Urology 2003;61:612e6.
4. Ou YC, Yang CR, Wang J, Cheng CL, Patel VR. Comparison of robotic-
assisted versus retropubic radical prostatectomy performed by a single
surgeon. Anticancer Res 2009;29:1637e42.
5. Ahlering TE, Skarecky D, Lee D, Clayman RV. Successful transfer of
open surgical skills to a laparoscopic environment using a robotic inter-
face: initial experience with laparoscopic radical prostatectomy. J Urol
2003;170:1738e41.6. Ou YC, Yang CR, Wang J, Cheng CL, Patel VR. Robotic-assisted radical
prostatectomy by a single surgeon in Taiwan: experience with the initial
30 cases. J Robotic Surg 2008;2:173e9.
7. Dasgupta P, Kirby RS. The current status of robot-assisted radical pros-
tatectomy. Asian J Androl 2009;11:90e3.
8. Sung ER, Jeong W, Park SY, Ham WS, Choi YD, Hong SJ, et al. The
“halo effect” in Korea: change in practice patterns since the introduction
of robot-assisted laparoscopic radical prostatectomy. J Robotic Surg 2009;
3:57e60.
9. Duchene DA, Moinzadeh A, Gill IS, Clayman RV, Winfield HN. Survey
of residency training in laparoscopic and robotic surgery. J Urol 2006;176:
2158e66.
10. Guru KA, Hussain A, Chandrasekhar R, Piacente P, Bienko M,
Glasgow M, et al. Current status of robot-assisted surgery in urology:
a multi-national survey of 297 urologic surgeons. Can J Urol 2009;16:
4736e41.
11. Coelho RF, Chauhan S, Palmer KJ, Rocco B, Patel MB, Patel VR.
Robotic-assisted radical prostatectomy: a review of current outcomes.
BJU Int 2009;104:1428e35.
12. Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, et al.
Retropubic, laparoscopic, and robot-assisted radical prostatectomy:
a systematic review and cumulative analysis of comparative studies. Eur
Urol 2009;55:1037e63.
13. Patel VR, Chammas Jr MF, Shah S. Robotic assisted laparoscopic radical
prostatectomy: a review of the current state of affairs. Int J Clin Pract
2007;61:309e14.
14. Nguyen MM, Kamoi K, Stein RJ, Aron M, Hafron JM, Turna B, et al.
Early continence outcomes of posterior musculofascial plate reconstruc-
tion during robotic and laparoscopic prostatectomy. BJU Int 2008;101:
1135e9.
15. Tewari A, Jhaveri J, Rao S, Yadav R, Bartsch G, Te A, et al. Total
reconstruction of the vesico-urethral junction. BJU Int 2008;101:
871e7.
16. Kaul S, Savera A, Badani K, Fumo M, Bhandari A, Menon M. Functional
outcomes and oncological efficacy of Vattikuti Institute prostatectomy
with veil of aphrodite nerve-sparing: an analysis of 154 consecutive
patients. BJU Int 2006;97:467e72.
17. Potdevin L, Ercolani M, Jeong J, Kim IY. Functional and oncologic
outcomes comparing interfascial and intrafascial nerve sparing in robot-
assisted laparoscopic radical prostatectomies. J Endourol 2009;23:
1479e84.
18. Descazeaud A, Peyromaure M, Zerbib M. Will robotic surgery become the
gold standard for radical prostatectomy? Eur Urol 2007;51:9e11.
19. Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H,
et al. Focal therapy for localized prostate cancer: a critical appraisal of
rationale and modalities. J Urol 2007;178:2260e7.
20. Ahmed HU, Moore C, Emberton M. Minimally-invasive technologies in
uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in
whole gland and focal therapy of localised prostate cancer. Surg Oncol
2009;18:219e32.
